PharmAbcine announced that it has signed a joint research agreement with Sanofi-Aventis Korea (Sanofi) to discover therapeutic antibody drug candidate. PharmAbcine will collaborate with Sanofi to discover therapeutic antibody drug candidate for targeting liver cancers which is one of the high incidence of disease in Asia through this joint research. PharmAbcine will focus on the discovery of antibody drug candidate with global level through its own fully human antibody library and know-how for novel drug development, and expects to upgrade the domestic biotechnology to a global level.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,915 KRW | -8.91% | -.--% | -22.27% |
1st Jan change | Capi. | |
---|---|---|
-22.27% | 63.77M | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.77% | 27.52B | |
-18.07% | 20.87B | |
-14.39% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- A208340 Stock
- News PharmAbcine Inc.
- PharmAbcine Signs Joint Research Agreement with Sanofi-Aventis Korea to Discover Therapeutic Antibody Drug Candidate